The Medical Letter on Drugs and Therapeutics
Semaglutide (Ozempic) for Weight Loss
April 5, 2021 (Issue: 1621)In recently published clinical trials, once-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of type 2 diabetes and to reduce the risk...more
- JPH Wilding et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.
- TA Wadden et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021 February 24 (epub).
- M Davies et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397:971.
- D Rubino et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021 March 23 (epub).
- Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015; 57:89.
- Diet, drugs, devices, and surgery for weight management. Med Lett Drugs Ther 2018; 60:91.
- SE Kanoski et al. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 2016; 310:R885.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.